President has made abundantly clear the u. S. Has not in any way indorse the decision that the government of turkey to mount a military incursion into northeast syria. President trump has emphasized to the government of turkey that they bear full responsibility for protecting the kurdish population and religious minorities including christians and ensuring that no humanitarian crisis takes place the ambassadors of e. U. Countries who sit on the Security Council we also came up with a joint statement we are deeply concerned by the Turkish Military operation in syria we call upon turkey to see is the unilateral military action as we do not believe it will address truckies underlying security concerns im told behind the scenes there be no discussions about those words with germany and france wanting to take a tougher line with turkey than the u. K. Statements from the German Government and from the french government has said that they condemn what is going on the Turkish Operation in the
Are with us. Lets start it off with you. This idea that it is one of the bigger sectors relatively speaking, the s p 500, but its also, remember, one of the fourth worst performing sectors so far. Say a look at the year to date losers. Interesting stories lines start to play out in terms of the particular stocks and themes drieding the trading. Kohls is down 19 and fossil, belts, watches, that sorts of thing, down 21 as well. If you take a look at some of the other stocks that perhaps are on the other side of this, you see the winners. Off price retail, tj max up 5 . Ulta budy up 10 . Lulu lemon is up 17 . The biggest one everyone talks about is one that hasnt gained a lot so far this year only up 5 year to date. Its amazon. Com. But remember, one of last years top performers and courtney, i got to sashgs one of the interesting things about this whole discussion is this idea of these stocks as melissa, i dont know if there is a theme that drives all these together. But retail definitel
Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders businesswireindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswireindia.com Daily Mail and Mail on Sunday newspapers.
(1)
Through the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia.
The new collaboration further expands Boehringer Ingelheim s circuitry-based approach to precision psychiatry and solidifies the company s commitment to provide better treatments for patients living with serious mental health conditions.
Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia. Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim s deep experience in central n